Program
acalabrutinib
Also written as “Acalabrutinib”, “ACP-196” and “Acalabrutinib (ACP-196)”.
Its studies are mostly in Leukemia, Lymphocytic, Chronic, B-Cell · Lymphoma, Mantle-Cell · Lymphoma, Large B-Cell, Diffuse · COVID-19 · Hepatic Insufficiency, led by 4 companies.
Drug pageAcalabrutinib: every studyAll 123 studies of it, academic ones too, with its approvals, label and forms.Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| AstraZenecaits history only | 5220 open or running | phase 4since Jun 11, 2021 | Jan 6, 2014 | Feb 15, 2027phase 3 · NCT02972840 |
| AbbVieits history only | 11 open or running | phase 3since May 20, 2024 | May 20, 2024 | Mar 2028phase 3 · NCT06428019 |
| Ascentage Pharma Group Internationalits history only | 11 open or running | phase 3since Mar 13, 2024 | Mar 13, 2024 | Aug 2027phase 3 · NCT06319456 |
| Ipsenits history only | 10 open or running | phase 2since Dec 29, 2021 | Dec 29, 2021 | none ahead |
Also a collaborator on its studies: Apices Soluciones S.L., Hoffmann-La Roche, Fortrea, eResearch Technology, CISCRP, Parexel, Merck and Eli Lilly.
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and studies of every company. Pick one to see its own:
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). An open circle marks the day WHO proposed its name. Dates ahead are the sponsors’ estimates.
Not listed one by one: 37 earlier studies, Jan 6, 2014 to Feb 22, 2021.
- Jun 9, 2015Named acalabrutinibINNProposed as its International Nonproprietary Name in WHO's List 113 · before, ACP-196
- Apr 28, 20212 phase 1 studiesAstraZeneca · NCT04867980, NCT04867941
- May 5, 20215 phase 1 studiesAstraZeneca · NCT04876807, NCT04901923, NCT04914936 and 2 more
- Jun 11, 2021Phase 4 study in Leukemia, Lymphocytic, Chronic, B-CellAstraZeneca · NCT04930536 · 103 enrolled · India
- Sep 16, 2021Phase 3 study in Leukemia, Lymphocytic, Chronic, B-CellAstraZeneca · NCT05057494 · 607 enrolled · United States, Australia, Czechia and more
- Dec 29, 2021Ipsen’s first study: phase 2 study in Hematologic NeoplasmsNew to IpsenIpsen · NCT05205252 · United States
- Jun 5, 2023Phase 2 study in Lymphoma, Mantle-CellAstraZeneca · NCT05951959 · 108 enrolled · United States, Australia, Brazil and more
- Jul 11, 2023Phase 2 study in Lymphoma, Large B-Cell, DiffuseAstraZeneca · NCT05952024 · 80 planned · United States, Brazil, Puerto Rico and more
- Mar 13, 2024Ascentage Pharma Group International’s first study: phase 3 study in CLL/SLLNew to Ascentage Pharma Group InternationalAscentage Pharma Group International · NCT06319456 · 344 planned · China
- May 20, 2024AbbVie’s first study: phase 3 study in Leukemia, Lymphocytic, Chronic, B-CellNew to AbbVieAbbVie · NCT06428019 · 170 planned · United States, Australia, France and more
- Aug 20, 2024Phase 4 study in Leukemia, B-CellAstraZeneca · NCT06651970 · 60 planned · United States, Czechia, Italy and more
- Jan 21, 2025Phase 2 study in Leukemia, Lymphocytic, Chronic, B-CellAstraZeneca · NCT06839872
- May 26, 2025Phase 2 study in Leukemia, Lymphocytic, Chronic, B-CellAstraZeneca · NCT07024706 · 80 planned · United States, Austria, Brazil and more
- Jun 12, 2025Phase 2 study in Lymphoma, Mantle-CellAstraZeneca · NCT07029737 · 55 planned · Spain
- Oct 5, 2026Primary completion moved from 2027-01-31 to 2027-04-30Date moved laterphase 3 · +3 months · NCT03836261
Ahead
- Feb 15, 2027Primary completion: phase 3 study in Lymphoma, Mantle-CellAstraZeneca · NCT02972840
- Feb 22, 2027Primary completion: phase 3 study in Lymphoma, Large B-Cell, DiffuseAstraZeneca · NCT04529772
- Apr 30, 2027Primary completion: phase 3 study in Leukemia, Lymphocytic, Chronic, B-CellAstraZeneca · NCT03836261
- Jul 15, 2027Primary completion: phase 3 study in Leukemia, Lymphocytic, Chronic, B-CellAstraZeneca · NCT05057494
TargetBeta
“An orally available inhibitor of Bruton's tyrosine kinase (BTK) ”NCIt, by rule
“Tyrosine-protein kinase BTK inhibitor; Tyrosine-protein kinase BTK inhibitor”ChEMBL 37, by rule
Other programs on BTK
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| ibrutinibrule | Johnson & Johnson | phase 4 | 78 |
| zanubrutinibrule | BeOne Medicines | phase 4 | 35 |
| pirtobrutinibrule | Eli Lilly | phase 4 | 30 |
| ritlecitinibrule | Pfizer | phase 3 | 42 |
| orelabrutinibrule | InnoCare Pharma | phase 3 | 27 |
| rilzabrutinibrule | Sanofi | phase 3 | 23 |
| evobrutinibrule | Merck KGaA, Darmstadt, Germany | phase 3 | 20 |
| fenebrutinib | Hoffmann-La Roche | phase 3 | 18 |
| nemtabrutinib | Merck | phase 3 | 16 |
| rocbrutinibrule | Lupeng Pharmaceutical | phase 3 | 15 |
| tirabrutinibrule | Gilead Sciences | phase 3 | 13 |
| birelentinibrule | Dizal Pharmaceuticals | phase 3 | 12 |
Studies
All 55 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Led by | Primary completion | Size |
|---|---|---|---|---|---|
| NCT07029737Lymphoma, Mantle-Cell · Spain | 2 | Recruiting | AstraZeneca | Dec 31, 2027 | 55 |
| NCT07024706Leukemia, Lymphocytic, Chronic, B-Cell · United States, Austria, Brazil and more | 2 | Recruiting | AstraZeneca | May 1, 2029 | 80 |
| NCT06839872Leukemia, Lymphocytic, Chronic, B-Cell | 2 | Withdrawn | AstraZeneca | Jul 28, 2028 | 0 |
| NCT06651970Leukemia, B-Cell · United States, Czechia, Italy and more | 4 | Recruiting | AstraZeneca | Sep 30, 2032 | 60 |
| NCT06428019Leukemia, Lymphocytic, Chronic, B-Cell · United States, Australia, France and more | 3 | Recruiting | AbbVie | Mar 2028 | 170 |
| NCT06319456CLL/SLL · China | 3 | Recruiting | Ascentage Pharma Group International | Aug 2027 | 344 |
| NCT05952024Lymphoma, Large B-Cell, Diffuse · United States, Brazil, Puerto Rico and more | 2 | Recruiting | AstraZeneca | Apr 22, 2029 | 80 |
| NCT05951959Lymphoma, Mantle-Cell · United States, Australia, Brazil and more | 2 | Active, not recruiting | AstraZeneca | Oct 31, 2028 | 108 |
| NCT05205252Hematologic Neoplasms · United States | 2 | Withdrawn | Ipsen | Jul 5, 2023 | 0 |
| NCT05057494Leukemia, Lymphocytic, Chronic, B-Cell · United States, Australia, Czechia and more | 3 | Active, not recruiting | AstraZeneca | Jul 15, 2027 | 607 |
| NCT04930536Leukemia, Lymphocytic, Chronic, B-Cell · India | 4 | Completed | AstraZeneca | May 2, 2023 | 103 |
| NCT04905043Healthy Volunteers · United States | 1 | Completed | AstraZeneca | Jul 11, 2016 | 12 |
| NCT04914936Healthy Participants · United States | 1 | Completed | AstraZeneca | Oct 16, 2014 | 72 |
| NCT04898101Healthy Volunteers · United States | 1 | Completed | AstraZeneca | Apr 13, 2016 | 14 |
| NCT04901923Healthy Participants · United States | 1 | Completed | AstraZeneca | May 22, 2014 | 59 |
| NCT04876807Healthy Volunteers · United States | 1 | Completed | AstraZeneca | Mar 15, 2016 | 36 |
| NCT04867980Healthy Volunteers · United States | 1 | Completed | AstraZeneca | May 9, 2016 | 48 |
| NCT04867941Hepatic Insufficiency · United States | 1 | Completed | AstraZeneca | Feb 2, 2015 | 18 |
| NCT04768985Bioequivalence · United States | 1 | Completed | AstraZeneca | May 10, 2021 | 66 |
| NCT04564040Lymphoma, Mantle-Cell · Germany | 1 | Completed | AstraZeneca | Dec 11, 2020 | 20 |
| NCT04529772Lymphoma, Large B-Cell, Diffuse · United States, Australia, Austria and more | 3 | Active, not recruiting | AstraZeneca | Feb 22, 2027 | 611 |
| NCT04489797Communicable Diseases · United States | 1 | Completed | AstraZeneca | Aug 28, 2020 | 35 |
| NCT04497948COVID-19 · Brazil | 1 | Terminated | AstraZeneca | Nov 18, 2020 | 9 |
| NCT04435483Pharmacokinetics · United States | 1 | Completed | AstraZeneca | Jun 26, 2020 | 39 |
| NCT04380688COVID-19 · United States | 2 | Completed | AstraZeneca | Nov 16, 2020 | 62 |
| NCT04346199COVID-19 · Argentina, Brazil, Chile and more | 2 | Completed | AstraZeneca | Nov 17, 2020 | 177 |
| NCT04075292Leukemia, Lymphocytic, Chronic, B-Cell · China, Philippines, Taiwan and more | 3 | Active, not recruiting | AstraZeneca | Jan 3, 2024 | 155 |
| NCT04008706Leukemia, Lymphocytic, Chronic, B-Cell · United States, Australia, Brazil and more | 3 | Completed | AstraZeneca | Nov 4, 2025 | 552 |
| NCT03968848Hepatic Insufficiency · United States | 1 | Completed | AstraZeneca | Mar 13, 2019 | 16 |
| NCT03932331Lymphoma, Mantle-Cell · China | 2 | Active, not recruiting | AstraZeneca | Dec 22, 2022 | 105 |
| NCT03836261Leukemia, Lymphocytic, Chronic, B-Cell · United States, Argentina, Australia and more | 3 | Active, not recruiting | AstraZeneca | Apr 30, 2027 | 984 |
| NCT03205046DLBCL · United States, United Kingdom | 2 | Terminated | AstraZeneca | Nov 20, 2019 | 25 |
| NCT03198650Part1: Advanced B-cell Malignancies · Japan | 1 | Completed | AstraZeneca | Oct 27, 2022 | 35 |
| NCT02972840Lymphoma, Mantle-Cell · United States, Argentina, Australia and more | 3 | Active, not recruiting | AstraZeneca | Feb 15, 2027 | 635 |
| NCT02970318Leukemia, Lymphocytic, Chronic, B-Cell · United States, Australia, Austria and more | 3 | Active, not recruiting | AstraZeneca | Sep 3, 2021 | 310 |
| NCT02735876Lymphoma, Mantle-Cell | 3 | Withdrawn | AstraZeneca | Jun 2020 | 0 |
| NCT02717611Leukemia, Lymphocytic, Chronic, B-Cell · United States, Belgium, France and more | 2 | Active, not recruiting | AstraZeneca | Oct 16, 2020 | 60 |
| NCT02717624Lymphoma, Mantle-Cell · United States, Italy, Poland | 1 | Active, not recruiting | AstraZeneca | Jun 15, 2022 | 72 |
| NCT02586857Glioblastoma · United States | 2 | Active, not recruiting | AstraZeneca | Jun 26, 2020 | 24 |
| NCT02537444Ovarian Neoplasms · United States | 2 | Completed | AstraZeneca | Jul 2018 | 78 |
| NCT02477696Leukemia, Lymphocytic, Chronic, B-Cell · United States, Australia, Belgium and more | 3 | Active, not recruiting | AstraZeneca | Sep 15, 2020 | 533 |
| NCT02475681Leukemia, Lymphocytic, Chronic, B-Cell · United States, Australia, Belgium and more | 3 | Completed | AstraZeneca | Feb 8, 2019 | 535 |
| NCT02454179Squamous Cell Carcinoma of Head and Neck · United States | 2 | Completed | AstraZeneca | May 2018 | 78 |
| NCT02448303Carcinoma, Non-Small-Cell Lung · United States | 2 | Completed | AstraZeneca | Mar 2018 | 74 |
| NCT02387762Arthritis, Rheumatoid · United States | 2 | Completed | AstraZeneca | May 2016 | 31 |
| NCT02362035Lymphoma, Follicular · United States | 2 | Completed | AstraZeneca | Jul 14, 2020 | 161 |
| NCT02362048Pancreatic Neoplasms · United States | 2 | Completed | AstraZeneca | Mar 2017 | 77 |
| NCT02351739Carcinoma, Transitional Cell · United States | 2 | Completed | AstraZeneca | Feb 2018 | 78 |
| NCT02337829Leukemia, Lymphocytic, Chronic, B-Cell · United States | 2 | Completed | AstraZeneca | Jun 26, 2020 | 48 |
| NCT02213926Lymphoma, Mantle-Cell · United States, Australia, Belgium and more | 2 | Active, not recruiting | AstraZeneca | Dec 4, 2020 | 124 |
| NCT02211014Multiple Myeloma · United States, United Kingdom | 1 | Completed | AstraZeneca | Apr 26, 2019 | 27 |
| NCT02180724Waldenstrom Macroglobulinemia · United States, France, Greece and more | 2 | Active, not recruiting | AstraZeneca | Oct 1, 2019 | 107 |
| NCT02180711Lymphoma, Non-Hodgkin · United States, Canada, Italy | 2 | Active, not recruiting | AstraZeneca | Aug 25, 2023 | 113 |
| NCT02112526Lymphoma, Large B-Cell, Diffuse · United States, United Kingdom | 1 | Completed | AstraZeneca | Jun 30, 2020 | 21 |
| NCT02029443Leukemia, Lymphocytic, Chronic, B-Cell · United States, Italy, United Kingdom | 2 | Active, not recruiting | AstraZeneca | Jul 15, 2021 | 306 |
How it is read
Names in the registry
- “Acalabrutinib”, 28 entries
- “acalabrutinib”, 7 entries
- “ACP-196”, 7 entries
- “Acalabrutinib (ACP-196)”, 3 entries
- “ACP-196 (acalabrutinib)”, 2 entries
Codes read as this program: ACP196.
Conditions, from the studies’ own filings
- Leukemia, Lymphocytic, Chronic, B-Cell, 14 studies
- Lymphoma, Mantle-Cell, 8 studies
- Lymphoma, Large B-Cell, Diffuse, 3 studies
- COVID-19, 3 studies
- Hepatic Insufficiency, 2 studies
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.